![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
ACTH Syndrome, Ectopic - 9 Studies Found
Recruiting |
: SOM230 Ectopic ACTH-producing Tumors : Ectopic ACTH Syndrome : 2016-04-26 : Drug: Pasireotide Other Name: SOM230 |
Terminated |
: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin :
: Drug: pasireotide LAR Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg pow |
Recruiting |
: Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome :
: Drug: Osilodrostat Osilodrostat will be prescribed by the investigator. Osirodrostat 1 mg, 5 mg, 10 mg, |
Recruiting |
: Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome : Cushing Syndrome : 2013-12-21 :
|
Terminated |
: Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion : Cushing's Syndrome : 2007-01-12 : Drug: Mifepristone Singe dose |
Completed |
: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome :
: 2011-06-07 : Drug: Mifepristone mifepristone at doses from 300mg/day up to 1200mg/day |
Completed |
: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome : Cushing's Syndrome : 2009-07-09 : Drug: mifepristone Mifepristone 300 mg to 1200 mg once daily |
Terminated |
: A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia : Cushing's Syndrome : 2008-11-20 : Drug: Cushing's syndrome confirmation Other Name: Provide access to standard test procedures. |
Completed |
: A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome : Cushing's Syndrome : 2007-12-05 : Drug: mifepristone Patients take mifepristone by mouth once a day. The dose is increased during schedule |